FDA Cleared ALS Platform Trial for Drug Registration
The FDA confirmed that the HEALEY ALS Platform Trial can support a New Drug Application for the investigational drug NUZ-001.
Updated on Oct. 6, 2026 in Alzheimer’s
Live Poll
Should the FDA streamline regulatory pathways to accelerate the approval of new medical treatments?
The FDA has confirmed that the HEALEY ALS Platform Trial Regimen I may serve as a registrational study for Neurizon's investigational amyotrophic lateral sclerosis treatment, NUZ-001. The agency also accepted the use of plasma neurofilament light chain biomarkers in the company's evidence package.
Why it matters
This regulatory feedback provides a clear pathway for Neurizon to advance its drug application process. By validating the use of the platform trial design and specific biomarkers, the FDA's guidance helps determine the company's long-term development strategy.
The FDA accepted the inclusion of plasma neurofilament light chain biomarkers in the evidence package for NUZ-001. Regimen I of the HEALEY ALS Platform Trial is now fully enrolled.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and medical devices in the United States.
Neurizon
Neurizon is a pharmaceutical company currently developing NUZ-001 for the treatment of amyotrophic lateral sclerosis.
The details
The FDA provided this guidance following a Type C meeting to discuss the regulatory pathway for NUZ-001. The trial utilizes a placebo-controlled design to evaluate clinically meaningful endpoints, which the agency now recognizes as sufficient for a potential registration filing.
Timeline
October 6, 2026: Neurizon announced the receipt of FDA written feedback.
Q1 2027: An NIH-funded expanded access program is expected to launch.
Q2 2027: Topline results from the HEALEY ALS trial are expected.
The Big Picture
This development aligns with the FDA's master protocol guidance for platform trials, which encourages efficient, multi-arm study designs. By permitting a single registrational trial for NUZ-001, the agency continues a trend of creating flexible pathways for rare disease treatments.
The FDA's decision potentially accelerates the timeline for bringing NUZ-001 to market, offering hope for new treatment options for those living with ALS. Patients may gain access to the drug sooner through the expanded access program scheduled for early 2027.
The takeaway
This regulatory update highlights the growing utility of platform trials in bringing therapies to patients with life-altering conditions more efficiently. Patients and families should monitor official trial updates as the 2027 readout approaches.
What happens next
Topline results from the HEALEY ALS Platform Trial Regimen I are expected in late Q2 2027, followed by an NIH-funded expanded access program in Q1 2027.
Further reading
For broader context on neurodegenerative disease research, visit the Alzheimer’s section.
Live Poll
Should the FDA streamline regulatory pathways to accelerate the approval of new medical treatments?
